- Home
- EXE vs MIST Comparison
EXE vs MIST Comparison
Compare EXE & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXE
- MIST
- Stock Information
- Founded
- EXE 1989
- MIST 2003
- Country
- EXE United States
- MIST Canada
- Employees
- EXE N/A
- MIST N/A
- Industry
- EXE
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- EXE
- MIST Health Care
- Exchange
- EXE NYSE
- MIST Nasdaq
- Market Cap
- EXE 24.7B
- MIST 53.9M
- IPO Year
- EXE 1993
- MIST N/A
- Fundamental
- Price
- EXE $112.66
- MIST $1.12
- Analyst Decision
- EXE Strong Buy
- MIST Strong Buy
- Analyst Count
- EXE 17
- MIST 2
- Target Price
- EXE $123.76
- MIST $9.50
- AVG Volume (30 Days)
- EXE 3.2M
- MIST 1.6M
- Earning Date
- EXE 04-29-2025
- MIST 05-20-2025
- Dividend Yield
- EXE 2.11%
- MIST N/A
- EPS Growth
- EXE N/A
- MIST N/A
- EPS
- EXE N/A
- MIST N/A
- Revenue
- EXE $6,568,000,000.00
- MIST N/A
- Revenue This Year
- EXE $158.16
- MIST N/A
- Revenue Next Year
- EXE $9.99
- MIST N/A
- P/E Ratio
- EXE N/A
- MIST N/A
- Revenue Growth
- EXE 35.62
- MIST N/A
- 52 Week Low
- EXE $69.12
- MIST $0.63
- 52 Week High
- EXE $114.03
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- EXE N/A
- MIST 46.48
- Support Level
- EXE N/A
- MIST $1.28
- Resistance Level
- EXE N/A
- MIST $1.32
- Average True Range (ATR)
- EXE 0.00
- MIST 0.12
- MACD
- EXE 0.00
- MIST 0.03
- Stochastic Oscillator
- EXE 0.00
- MIST 38.80
About EXE EXPAND ENERGY CORPORATION
Expand Energy Corp independent natural gas producer in the United States. It is fueling a more affordable, reliable and lower-carbon future. The group focused on developing abundant natural gas, oil, and gas liquids to expand energy access.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).